# A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer

> **NCT07223567** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Rectal Cancer
- Rectal Cancer Recurrent

## Interventions

- **DRUG:** Regorafenib
- **DRUG:** Lorigerlimab

## Key facts

- **NCT ID:** NCT07223567
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-10-27
- **Primary completion:** 2026-01-22
- **Final completion:** 2026-01-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 0 participants enrolled
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07223567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07223567, "A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07223567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*